MJFF showcases Parkinson’s disease advances by Kinemed

"Research over the last decade has revealed this disease tobe much more complex than was thought at first, and we now understand whyearlier generations of drugs that focused on a single metric, such as dopaminelevel, could not provide a cure," Fineman adds. "Just as a physician is able todirectly ask a patient whether he's feeling better, a single cerebrospinalfluid sample allows us to directly query the overall health of living neuronswithin the brain. Our unique ability to sample several pathways simultaneouslynot only detects whether patients have Parkinson's or other neurodegenerativeconditions, but also enables us to monitor progression and therapeutic reversalof underlying, disease-driving processes that are responsible for a patient'sclinical course. This measurement approach enables drug developers to knowearly on if their investigational therapies have genuine disease-modifyingeffects that allow neurons to recover."